



LEARNER NOTIFICATION

Society of Cardiovascular Anesthesiologists

Activity Title: 2026 SCA Annual Meeting and Workshops

Date: April: 23-26, 2026

Format: Live, In-person

Acknowledgement of Monetary Commercial Support

The following company provided monetary support for this CME educational activity in the form of an unrestricted educational grant: **None**

Acknowledgement of In-Kind Support

The following companies provided in-kind support for this CME educational activity: Advance TEE: GE (3 Venue Fit, 2 Logiq e, 3 Vivid Pioneer, 2 Vivid E95, 4 EchoPac Laptop); Philips (2 Lumify, 5 EPIQ CVx, 2 Flash 5100POC, 2 Compact 5500P, 11 laptops, X8-2t - qty 5, X11-4t - qty 3, X5-1c - qty 5, S5-1 - qty 4, C5-1 - qty 3, eL18-4 - qty 5); ECMO: Getinge (2-ECMO & cannulas); Abiomed (Impella); Regional: GE (3 Venue Fit, 2 Logiq e, 3 Vivid Pioneer, 2 Vivid E95, 4 EchoPac Laptop); Philips (2 Lumify, 5 EPIQ CVx, 2 Flash 5100POC, 2 Compact 5500P, 11 laptops, X8-2t - qty 5, X11-4t - qty 3, X5-1c - qty 5, S5-1 - qty 4, C5-1 - qty 3, eL18-4 - qty 5); 3D TEE: GE (3 Venue Fit, 2 Logiq e, 3 Vivid Pioneer, 2 Vivid E95, 4 EchoPac Laptop); Philips (2 Lumify, 5 EPIQ CVx, 2 Flash 5100POC, 2 Compact 5500P, 11 laptops, X8-2t - qty 5, X11-4t - qty 3, X5-1c - qty 5, S5-1 - qty 4, C5-1 - qty 3, eL18-4 - qty 5); POCUS: GE (3 Venue Fit, 2 Logiq e, 3 Vivid Pioneer, 2 Vivid E95, 4 EchoPac Laptop); Philips (2 Lumify, 5 EPIQ CVx, 2 Flash 5100POC, 2 Compact 5500P, 11 laptops, X8-2t - qty 5, X11-4t - qty 3, X5-1c - qty 5, S5-1 - qty 4, C5-1 - qty 3, eL18-4 - qty 5); Structural Heart: GE (3 Venue Fit, 2 Logiq e, 3 Vivid Pioneer, 2 Vivid E95, 4 EchoPac Laptop); Philips (2 Lumify, 5 EPIQ CVx, 2 Flash 5100POC, 2 Compact 5500P, 11 laptops, X8-2t - qty 5, X11-4t - qty 3, X5-1c - qty 5, S5-1 - qty 4, C5-1 - qty 3, eL18-4 - qty 5); Edwards (One (1) TAVR Simulator); Medtronic (ICD models)



Accreditation Statement

The Society of Cardiovascular Anesthesiologists is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Society of Cardiovascular Anesthesiologists designates this live activity for a maximum of 26.25 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification in Anesthesiology[™] program and MOCA[®] are registered trademarks of The American Board of Anesthesiology[®].

CREDIT DESIGNATION

This activity offers up to 26.25 CME credits, of which 13.75 credits contribute the patient safety CME component of the American Board of Anesthesiology's redesigned Maintenance of Certification in Anesthesiology™ (MOCA®) program, known as MOCA 2.0®. Please consult the ABA website, www.theABA.org, for a list of all MOCA 2.0 requirements.

Description:

Annual subspecialty society meeting that presents educational content and scientific research for cardiovascular anesthesiologists. Teaching modalities include didactic lectures, interactive panel discussions, case discussion sections, presentations of original scientific work, workshops for developing technical and cognitive skills, and small group discussions. Many sessions and panel discussions are comprised of multidisciplinary faculty, including experts in the field of Cardiothoracic surgery, Thoracic surgery, Cardiology as well as Cardiac Anesthesiology. Specific topics include Structural Heart Procedures, Enhanced recovery after cardiac surgery, updates on relevant clinical guidelines, Finances in medicine, Adult Congenital Heart Disease, Transplantation, Echocardiography, Mechanical Circulatory Support, Management of Heart Failure, and international cardiac anesthesiology.

Educational Information

Physician Practice Gap:

Artificial intelligence (AI) is rapidly advancing in perioperative medicine, offering tools for risk prediction, image analysis, workflow optimization, and clinical decision support. However, most cardiac anesthesiologists have limited familiarity with AI applications, data interpretation, and integration into practice. Without targeted education, there is a risk of underutilization, misapplication, or resistance to adoption. Bridging this gap is essential to ensure clinicians can critically evaluate and effectively implement AI-driven tools to improve patient outcomes.

Transcatheter tricuspid valve interventions (TTVIs) are expanding treatment options for high-risk patients, but many cardiac anesthesiologists and perioperative providers are unfamiliar with these procedures. Gaps exist in knowledge of patient selection, anesthetic management, imaging, and team coordination. Education is needed to align clinical practice with evolving standards and improve outcomes.

The growing population of adults with congenital heart disease (ACHD) presents unique and complex challenges in perioperative care. Many cardiac anesthesiologists have limited exposure to ACHD physiology, prior surgical repairs, and associated comorbidities. As these patients increasingly require noncardiac and cardiac interventions, there is a critical need to improve anesthetic planning, risk stratification, and multidisciplinary coordination. Targeted education is essential to close this gap and ensure safe, individualized care.

Needs that Underlie the Gap

- Updated Clinical Knowledge – Education on the latest advancements in transcatheter tricuspid valve interventions (TTVI), including patient selection, procedural workflows, intraoperative imaging, and anesthetic considerations.
- Specialized Training – Deeper understanding of the complex physiology and prior repairs in adult congenital heart disease (ACHD) patients, including implications for anesthetic management and perioperative planning.
- Technological Literacy – Foundational knowledge and critical appraisal skills for integrating artificial intelligence (AI) tools into clinical practice, including applications in monitoring, imaging, risk stratification, and decision support.

Overall, learners need case-based, hands-on, and interdisciplinary approaches to build competence and confidence in applying evolving techniques and technologies in cardiac anesthesia practice.

DESIGNED to Change/Outcome:

This activity is designed to change participants' knowledge of current and emerging AI applications, competence in critically evaluating AI tools, and performance in appropriately integrating AI-driven decision support into perioperative care and improve knowledge of patient selection criteria as well as procedural considerations, enhance competence in intraoperative management of TTVI cases, and support performance in team-based perioperative planning and execution. Finally, this activity is designed to increase knowledge of ACHD physiology and surgical history, improve competence in tailoring anesthetic plans, and enhance performance in the perioperative care of this growing and complex patient population.

Educational Objectives

After completing this activity, the participant should be better able to:

1. Describe the latest advances in perioperative cardiovascular medicine.
2. Identify current trends in clinical and bench research pertinent to cardiovascular medicine and incorporate this knowledge into understanding of the science of cardiothoracic and vascular anesthesia.
3. Evaluate new therapeutic techniques and diagnostic/interventional procedures in cardiothoracic and vascular anesthesiology.
4. Discuss quality of care issues, including applicable metrics, as mechanisms to assist with quality improvement at the learner's institution and address the evolving financial landscape of medical practice.
5. Discuss advances in clinical echocardiography and point-of-care ultrasound and how to use them to improve outcomes in cardiac surgical patients. This will include performance of technical skills and discussion of their clinical applications.
6. Acquire skills necessary for career progression and development in cardiovascular and thoracic anesthesia.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Partial credit for individual sessions is not available.

Contact Information

If you have questions regarding your CME certificate, please contact Faith Oyedepo, Foyedepo@veritasamc.com.

Disclosure of Financial Relationships

As an accredited provider of the ACCME, SCA adheres to all ACCME Standards for Integrity and Independence in Accredited Continuing Education. The following individuals in control of content development for this activity have indicated that they do have financial relationships with ACCME defined ineligible companies within the past 24 months. All financial relationships have been mitigated. All others in control of content not listed below have indicated that they have no financial relationships to disclose.

| Last Name | First Name | Name of Commercial Interest(s) | Individual's Role(s) in Activity | Mechanism(s) implemented to resolve conflict of interest appropriate to role(s) in the activity |
|-----------|------------|--|----------------------------------|--|
| Barker | Colin | Abbot Vascular: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Boston Scientific: Consulting Fees (Ongoing); Edwards Life Science: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Medtronic: Consulting Fees (Ongoing) | Workshop Faculty | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Bartoszko | Justyna | Canadian Blood Services: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Canadian Institutes of Health Research: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Grifols: Honoraria (Ongoing) Grifols: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Heart and Stroke Foundation of Canada: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Octapharma AG: Advisory Board (Ongoing); Octapharma AG: Consulting Fees (Ongoing); Octapharma AG: Honoraria (Ongoing); Octapharma AG: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |

| | | | | |
|---------|---------|--|--------------------|--|
| Belani | Kiran | GE Healthcare: Consulting Fees (Ongoing) | Moderator; Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Brod | Jessica | Cyban Pty Ltd: Advisory Board (Ongoing); Cyban Pty Ltd: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing) | Workshop Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Crowley | Jerome | Johnson & Johnson: Consulting Fees (Ongoing) | Workshop Faculty | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |

| | | | | |
|----------|---------|--|--------------------|--|
| Duncan | Andra | Hemosonics LLC: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Octapharma: Advisory Board (Ongoing) | Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Ender | Joerg | Abbott: Consulting Fees (Ongoing); Abbott: Honoraria (Ongoing); BD: Honoraria (Ongoing); Edwards Life Sciences: Honoraria (Ongoing); Medela: Honoraria (Ongoing); Philips: Consulting Fees (Ongoing); Philips: Honoraria (Ongoing) | Moderator, Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Essandoh | Michael | Abiomed/J&J MedTech: Consulting Fees (Ongoing); Boston Scientific: Consulting Fees (Ongoing) | Workshop Faculty | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |

| | | | | |
|----------------|-----------|---|-----------------------------|--|
| Fielding-Singh | Vikram | Calcimedica: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); PyrAmes: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Seastar Medical: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing) | Moderator, Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Fuller | Stephanie | WL Gore: Consulting Fees (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Goeddel | Lee | Edwards Life Science: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Retia Medical: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing) | Speaker; Workshop Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |

| | | | | |
|--------|------|---|------------------------------|--|
| Harvey | Reed | Atricure: Consulting Fees (Ongoing) | Moderator; Discussion Leader | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Heerdt | Paul | BD: Consulting Fees (Ongoing); Cardiage LLC: Consulting Fees (Ongoing); Edwards Life Science: Consulting Fees (Terminated, January 1, 2025); Edwards Life Science: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, January 1, 2025); emka Medical: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |

| | | | | |
|---------|------------|---|--------------------|--|
| Hensley | Nadia | Octapharma USA: Advisory Board (Terminated, October 28, 2025); Octapharma USA: Consulting Fees (Terminated, October 28, 2025) | Speaker; Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Hoyler | Marguerite | Cerus: Honoraria (Terminated, October 22, 2025) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Janda | Allison | Biointellisense, Inc.: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Hiasco-USA Pharmaceuticals: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |

| | | | | |
|--------|--------|--|--------------------|--|
| Joshi | Ravi | Octapharma USA: Advisory Board (Ongoing); Octapharma USA: Consulting Fees (Ongoing); SERB pharmaceuticals: Advisory Board (Ongoing); SERB pharmaceuticals: Consulting Fees (Ongoing) | Panelist | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Kertai | Miklos | Grifols: Advisory Board (Terminated, November 11, 2025); Octapharma USA: Advisory Board (Terminated, November 11, 2025) | Speaker; Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |

| | | | | |
|---------|---------|--|------------------|--|
| Kleiman | Amanda | Medtronic: Consulting Fees (Terminated, December 31, 2024) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Lander | Heather | BD Life Sciences: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); BD Life Sciences: Salary (Ongoing) | Workshop Faculty | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |

| | | | | |
|--------|----------|--|------------------|--|
| Leff | Jonathan | Octapharma: Advisory Board (Terminated, October 9, 2025) | Workshop Faculty | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |
| Lester | Laeben | AirSupport: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Cycleron: Advisory Board (Ongoing) | Workshop Faculty | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |

| | | | | |
|---------|-------|--|-----------|--|
| Lewis | Choy | La Jolla Pharmaceutical Company: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated) | Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Lindman | Brian | Anteris: Consulting Fees (Ongoing); Edwards Lifesciences: Consulting Fees (Ongoing); Edwards Lifesciences: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Kardigan: Advisory Board (Ongoing); Kardigan: Consulting Fees (Ongoing); Medtronic: Consulting Fees (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |

| | | | | |
|--------|----------|---|---------|--|
| Mathis | Michael | Chiesi, USA: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Mazer | C. David | Ontario Nursing Association: Consulting Fees (Terminated); VarmX: Advisory Board (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |

| | | | | |
|-----------|---------|---|---|--|
| Mazzeffi | Michael | Cellphire: Consulting Fees (Terminated); Grifols: Consulting Fees (Terminated); Hemosonics: Consulting Fees (Terminated); NovoNordisk: Consulting Fees (Terminated); Octapharma: Consulting Fees (Terminated); Takeda Pharmaceuticals: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing) | Speaker; Workshop Faculty; Workshop Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| McCartney | Sharon | Humacyte Inc.: Consulting Fees (Terminated, December 1, 2024) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |

| | | | | |
|-------------|--------------|--|-----------|--|
| Meng | Marie-Louise | BD: Advisory Board (Ongoing); BD: Consulting Fees (Ongoing); BD: Honoraria (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Methangkool | Emily | Medtronic: Honoraria (Ongoing) | Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |

| | | | | |
|-----------|--------|---|--|--|
| Neuburger | Peter | Medtronic Inc: Honoraria (Terminated, July 31, 2025) | Speaker; Workshop Moderator; Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Oliver | Ashley | Medtronic: Advisory Board (Ongoing); Medtronic: Consulting Fees (Ongoing) | Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |

| | | | | |
|-----------|--------|--|---------|--|
| Pelletier | Marc | Johnson & Johnson: Advisory Board (Ongoing); Medtronic Inc: Advisory Board (Ongoing); ProCell: Consulting Fees (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Perry | Tjorvi | Edwards Life Science: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated early 2025); Octapharma: Advisory Board (Ongoing); Octapharma: Consulting Fees (Ongoing); Octapharma: Honoraria (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |

| | | | | |
|---------|---------|---|---------------------------|--|
| Raphael | Jacob | CSL-Behring: Consulting Fees (Terminated October 2025); Octapharma USA: Consulting Fees (Terminated October 2025); Werfen: Consulting Fees (Terminated February 2024) | Speaker; Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Shernan | Stanton | Philips: Consulting Fees (Ongoing) | Speaker; Workshop Faculty | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |

| | | | | |
|------------|-------|---|------------------|--|
| Shillcutt | Sasha | Brave Enough LLC (My personal blog and website for wellness in women.): Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Sniecinski | Roman | Anesthesia Labs Inc.: Advisory Board (Ongoing); Anesthesia Labs Inc.: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Grifols SSNA: Advisory Board (Ongoing); Grifols SSNA: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Tractio Diagnostics: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing) | Workshop Faculty | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |

| | | | | |
|---------|---------|----------------------------------|--------------------|--|
| Spence | Jessica | VarmX: Consulting Fees (Ongoing) | Moderator | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Steppan | Jochen | Medtronic: Honoraria (Ongoing) | Moderator; Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |

| | | | | |
|--------|---------|---|----------|--|
| Tanaka | Kenichi | CSL Berhing: Consulting Fees (Ongoing); Grifols: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, September 24, 2025); HikariDx: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Octapharma AG: Consulting Fees (Ongoing); VarmX: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Tong | Zhen Yu | Abbott Medical: Honoraria (Ongoing); abiomed: Honoraria (Ongoing); LIFENET: Honoraria (Ongoing) | Panelist | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. |

| | | | | |
|----------|-------------|--|---------------------------|--|
| Troianos | Christopher | CoMind: Advisory Board (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Usman | Asad | abiomed: Honoraria (Ongoing); Keystone perfusion: Advisory Board (Ongoing); Spectrum Medical: Advisory Board (Ongoing) | Speaker; Workshop Faculty | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |

| | | | | |
|-----------|---------|--|-----------------------------|--|
| Vanneman | Matthew | Dana-Farber Cancer Insitute/Novartis: Royalties (Terminated, March 16, 2024) | Speaker; Workshop Faculty | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Wakefield | Brett | Abiomed: Honoraria (Ongoing) | Moderator; Workshop Faculty | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |

| | | | | |
|----------|---------|--|--------------------|--|
| Williams | Tiffany | BD Life Sciences: Advisory Board (Ongoing); BD Life Sciences: Consulting Fees (Ongoing) | Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |
| Zakaria | Luai | BTG pharmaceuticals: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, October 31, 2025) | Moderator; Speaker | No conflict of interest exists. SCA requires all individuals with financial relationships with ACCME defined ineligible companies to comply with ACCME Standards for Commercial Support. SCA has received an attestation from this presenter/planner agreeing to comply. In addition, speaker presentations were reviewed by the CME committee and there were no conflicts identified. |

How to Get Your CME Certificate

1. Go to <https://www.surveymagnet.com/magnet3/login.asp?EventKey=QYTTZLWQ> (link will become active at the conclusion of the meeting)
2. Login and evaluate the meeting.
3. Print all pages of your certificate for your records.